Airway Epithelial Cell Peroxisome Proliferator-Activated Receptor {gamma} Regulates Inflammation and Mucin Expression in Allergic Airway Disease [MUCOSAL IMMUNOLOGY]

Airway epithelial cells (AECs) orchestrate inflammatory responses to airborne irritants that enter the respiratory system. A viscous mucus layer produced by goblet cells in the airway epithelium also contributes to a physiological defense mechanism through the physical and chemical barriers it provides. Dysregulation or impairment in these functions has been implicated as a cause of the chronic inflammation and tissue remodeling that constitute major pathological features of asthma. In particular, mucus hypersecretion leading to airway obstruction and impaired pulmonary function is associated with morbidity and mortality in asthma patients. Peroxisome proliferator–activated receptor (PPAR) is a ligand-activated transcription factor involved in a variety of cellular processes. Accumulating evidence indicates that PPAR agonists antagonize exaggerated inflammatory responses, yet PPAR's precise role in airway remodeling/mucus hypersecretion has yet to be defined. In this study, we created an AEC-specific PPAR (AEC-PPAR) deletion to investigate PPAR's functions in a murine model of allergic airway disease. AEC-PPAR deficiency exaggerated airway hyperresponsiveness, inflammation, cytokine expression, and tissue remodeling. We also found that PPAR directly bound to a PPAR response element found in MUC5AC and repressed gene expression. Likewise, PPAR regulated mucin and inflammatory factors in primary human bronchial epithelial cells. In light of the current standard therapies' limited and inadequate direct effect on airway mucus hypersecretion, our study showing AEC-PPAR's role as a transcriptional repressor of MUC5AC highlights this receptor's potential as a pharmacological target for asthma.

https://ift.tt/2NKfxBz